

Future Perspectives of Transdermal Patches- A Review

Samreen Fatima and Deepika B

St Pauls College of Pharmacy, Affiliated to OU, Turkayamjal, RR dist.

Abstract: Transdermal Drug Delivery Systems- in the form of patch is treated as a special drug candidate to transdermal administration. The required properties of suitable drugs for patches were high hepatic- first pass effect, and its high lipophilicity, low molecular weight means i.e., having high capacity to cross the skin membrane. A matrix type design is suitable with patch- because of ease manufacturing. So, possible for transdermal patch to release the drug slowly via skin membrane for prolonged period of time and decreases the the frequency of dose administration, which is helpful for the treatment of various diseases. Thus, objective of this study is to provide knowledge on transdermal patches.

Keywords: Transdermal patches, Challenges, Future perspectives, Matrix design.

INTRODUCTION

Transdermal delivery gives a controlled, administration of drug, and allows the continuous input with short half-lives, which eliminates rapid entry of drug into systemic (blood) circulation. Patches deliver therapeutically required effective concentration of drug across the skin membrane, patch release the active ingredients into blood circulation through skin barriers. The patch contains high amount dose of drug, which retains on the skin for more long period of time, get into blood circulation via diffusion.

TDOS offers benefits over customary infusion and oral strategies. It decreases the heap that oral course generally puts on the intestinal system and liver, which upgrades patient consistence and limits hurtful results of a medication caused from brief excess. It is helpful, particularly eminent in patches which require just once week after week application. Such a basic dosing routine guides in patient adherence to drug therapy [Dhiman, S. *et al.*, 2011].

Oral course is the most well known course of medication conveyance framework yet it has a few disservices including first pass digestion, drug debasement and so on in gastrointestinal lot because of catalysts, pH and so forth. To defeat these issues, a clever medication conveyance framework was created by (chien, *et al.*, 1992, Banker, *et al.*, 1990, Guy, *et al.*, 1996), transdermal conveyance framework. Medication can infiltrate through skin by means of three pathways-

A] By hair follicles. b) By sebaceous organs. c) By sweat conduit.

This medication conveyance frameworks, utilized in different skin issues, likewise in administration

of diseases torments, smoking discontinuance and neurological issues [Sultana, A. *et al.*, 2021].

Properties

Physical Properties

The medication ought to have a sub-atomic weight under 1000 Daltons.

The medication ought to have fondness for both lipophilic and hydrophilic stage. Outrageous apportioning attributes are not conducive to effective medication conveyance through the skin.

The medication ought to have low dissolving point.

Alongside these properties the medication ought to be powerful, having short half-life and be non-bothering.

Chemical Properties

Medication ought to be exceptionally strong, for example it ought to be compelling in barely any mg/day

- The medication have short half-life.
- The medication ought not to be aggravation and non-adversely affected.
- The medication ought to steady when contact with skin.
- They shouldn't invigorate an invulnerable response to the skin.
- Resistance to medication shouldn't foster and zero request discharge profile of transdermal conveyance.
- Portion is under 50 mg each day and preferably under 10 mg each day.
- The medication shouldn't get bound in subcutaneous tissue.
- The medication shouldn't get broadly utilized in skin [Tanwar, H. *et al.*, 2016].

Drug Selection for Transdermal Patch [Saroha, K. *et al.*, 2011]:


- Dose to be less, Half-life to be less.
- Sub-atomic weight ought to be less than 400.
- Log P between 1.0 to 4.
- Penetrability coefficient to be $<0.5 \times 10^{-3} \text{cm}^2 \text{ per hr}$.
- Medication to be non-aggravating, and non-sharpening to the skin.
- Oral bioavailability must low, therapeutic index also to be low.

Advantages

- Avoids first pass hepatic metabolism.

- Maintaining a stable, controlled level of drug in blood.
- Characteristics comparable.
- Extended duration.
- No interference (gastric fluid or intestinal fluid).
- Suitable for the administration of drugs with high potency E.g. nitroglycerine, with narrow therapeutic window.

Disadvantages: The route is not suitable if: drug dose is more, drug has high molecular size (absorption is more difficult; less than 800-1000 Daltons).3. If the drug is irritating. 4. Drugs are metabolized within the skin. 5. Undergoes- protein binding.

Techniques for enhancing Drug delivery through transdermal route**Preparation of Transdermal Patches****Mercury Substrate Method** [Prabhakar, D. *et al.*, 2013]

The required amount of drug must be dissolved in a suitable polymer- solution along with a selected plasticizer. Solution must be converted to a homogenous dispersion by stirring with mechanical stirrer, and then poured onto a petri dish containing glass ring, for (placed over the mercury surface). Covered with a funnel placed, for drying the patches, patches were stored with in a desiccator.

By Using IPM Membranes Method [Prabhakar, D. *et al.*, 2013]

The drug is scattered in a combination of water-, propylene glycol containing polymer (carbopol940), and stirred for 12hrs in magnetic stirrer, made viscous by the tri ethanolamine. Converted to gel with buffer pH 7.4 can be utilized get solution gel, it is consolidated in the IPM membrane.

By Using EVAC Membranes Method [Prabhakar, D. *et al.*, 2013]

If the drug isn't soluble in water, propylene glycol (PG) solvent is used, by dissolving drug in propylene glycol; and neutralized by utilizing 5% w/w sodium hydroxide solution, carbopol resin added. It is (in gel structure) is kept on a layer covering the predetermined region. A rate controlling membrane kept on the gel, and the edges were fixed by intensity to get a sealed gadget.

Aluminium Backed Adhesive Film Method [Sultana, A. *et al.*, 2021]

TDSS might create temperamental grids in the event that the stacking portion by Aluminium backed adhesive film method. For preparation, chloroform is dissolvable; the medication is disintegrated in the chloroform and sticky material to be added and broke up. A specially designed aluminium previous fixed with aluminium foil, the finishes with fitting plug blocks.

Asymmetric TPX Membrane Method [Sultana, A. *et al.*, 2021]

A patch can be manufactured by an intensity sealable polyester film with a sunken of 1cm width utilized as the support layer. Drug test is administered into the inward layer, covered by {poly (4-methyl-1pentene)} asymmetric membrane, furthermore, fixed by the adhesive.

By Using Free Film Method [Tanwar, H. *et al.*, 2016]

The film of cellulose acetate - patch is prepared by projecting the solution on to the mercury surface, at a concentration of 40% w/w of polymer weight, the plasticizers are integrated, and the polymer solution was poured onto a petri dish in a glass ring, that which is put on the mercury surface. The rate of evaporation of the solvent is constrained by setting an inverted funnel over the petri dish, the film formation is noted, by the mercury surface after complete evaporation of the solvent.

Evaluation Test of Transdermal Patches

The prepared Tce patches were evaluated for following tests.

Folding Endurance: The patch was folded repeatedly till it broke. The point at which it was stable without breaking was considered as folding endurance. The folding endurance was determined for 4 patches from each formulation.

Thickness: vernier calipers' was used to determine the thickness of Patch. Selected 4 patches randomly from each formulation and determined the thickness.

Uniformity of Weight: selected 4 patches from each formulation and measured the weights by weighing balance (contech).

Moisture Content: The patches were weighed and kept in desiccators containing calcium chloride for 24 hrs and measured the weights again to calculate the moisture present in the patches (Long Mo, *et al* 2022).

Moisture Uptake: The patches were weighed and kept in desiccators containing potassium chloride for maintaining humidity for 24 hrs and measured the weights again to calculate the moisture absorbed by the patches (Long Mo, *et al* 2022).

In-vitro Permeation study: Franz diffusion cell was used and the selected rat abdominal skin of rat was placed between the donor and receptor compartments, receptor compartment was filled with 18 ml of pH 5.4 acetate buffer and a magnetic

bead. The apparatus was placed on magnetic stirrer, maintained the temperature of $32 \pm 0.5^{\circ}\text{C}$ for 8 hrs. at different time intervals 1ml of sample was removed and replaced with fresh acetate buffer. The collected samples were analyzed by spectrophotometer (Electro lab) at 296nm (Long Mo, *et al* 2022).

CONCLUSION

The transdermal drug delivery gives information about the drug delivery and its assessment process details. It is a painless, helpful and possibly viable method for conveying regular dose of numerous medications; patches are the most widely recognized type of delivery of drug, that a medication has right blend of physical, chemical and pharmacology, transdermal delivery is a remarkable successful course of administration. Transdermal dosage forms might give clinicians a valuable chance to offer more therapeutic choices to their patients to enhance their care, the utilization of various biophysical procedures has aided in our interpret the nature of the stratum corneum boundary and the manner by which chemical compounds collaborate with and impact this design. A superior understanding of the collaboration of enhancers with the stratum corneum and the improvement of structure activity connections for enhancers will support the plan of enhancers with ideal qualities and negligible toxicity.

REFERENCES

1. Mo, L., Lu, G., Ou, X. and Ouyang, D. "Formulation and development of novel control release transdermal patches of carvedilol to improve bioavailability for the treatment of heart failure." *Saudi Journal of Biological Sciences* 29.1 (2022): 266-272.
2. Victoria, C., Cottrell, J. and South, C. "Transdermal Delivery Patch." United States Patent, 28th may (2015): 1-33.
3. Dhiman, S., Singh, T.G. and Rehni, A.K. "Transdermal patches: a recent approach to new drug delivery system." *Int J Pharm Pharm Sci* 3.5 (2011): 26-34.
4. Sultana, A., Birajdar, V., Madhav, K.V., Kiranmai, M. and Sravanthi, "A review on novel drug delivery system-Transdermal Drug Delivery System and its statistics." *Journal of Global Trends in Pharmaceutical Sciences* 12.3 (2021): 9564-9580.
5. Sunitha, R.M. and Mayuri, B. "Transdermal Drug Delivery System-A Review." *Journal of*

- Global Trends in Pharmaceutical Sciences* 12.2 (2021): 9418-9425.
6. Sharma, N., Agarwal, G., Rana, A.C., Bhat, Z.A. and Kumar, D. "A Review: Transdermal Drug Delivery System: A tool for novel drug delivery system." *International Journal of Drug Development and Research* 3.3 (2011): 0975-9344.
 7. Tanwar, H. and Sachdeva, R. "Transdermal drug delivery system: A review." *International journal of pharmaceutical sciences and research* 7.6 (2016): 2274-90.
 8. Al Hanbali, O.A., Khan, H.M.S., Sarfraz, M., Arafat, M., Ijaz, S. and Hameed, A. "Transdermal patches: Design and current approaches to painless drug delivery." *Acta Pharmaceutica* 69.2 (2019): 197-215.
 9. Prabhakar, D., Sreekanth, J. and Jayaveera, K.N. "Transdermal drug delivery patches: A review." *Journal of Drug Delivery and Therapeutics* 3.4 (2013): 231-221.
 10. Saroha, K., Yadav, B. and Sharma, B. "Transdermal Patch: A discrete dosage form." *International Journal of Current Pharmaceutical Research* 3.3 (2011): 98-108.
 11. Mutalik, S., Udupa, N., Kumar, S., Agarwal, S., Subramanian, G. and Ranjith, A.K. "Glipizide matrix transdermal Systems for diabetes mellitus: preparation, in vitro and preclinical studies." *Life Sciences* (2005).
 12. Mutalik, S. and Udupa, N. "Glibendomide - transdermal patches: physicochemical, pharma codynamic, and pharmacokinetic evaluations." *Journal of pharmaceutical sciences* (2003).
 13. Sharma, P., Dwivedee, B.P., Bisht, D., Dash, A.K. and Kumar, D. "The chemical constituents and diverse. Pharmacological importance of *Tinospora cordifolia*." *Life Sciences*. 5.9 (2019): e02437.
 14. Chilka, R.M., Kamalapurkar, K. A. and paralkar, S.D. "Formulation and Development of Topical Gel of *Tinospora Cordifolia* as Antimicrobial Agent." *Asian Journal of Research in chemistry and pharmaceutical Sciences* (2020).
 15. Shingade, G.M. "Review on: recent trend on transdermal drug delivery system." *Journal of drug delivery and therapeutics* 2.1 (2012).
 16. Tan, H.S. and Pfister, W.R. "Pressure-sensitive adhesives for transdermal drug delivery systems." *Pharmaceutical Science & Technology Today* 2.2 (1999): 60-69.
 17. Farah, S., Anderson, D.G. and Langer, R. "Physical and mechanical properties of PLA, and their functions in widespread applications—A comprehensive review." *Advanced drug delivery reviews* 107 (2016): 367-392.
 18. Mo, L., Lu, G., Ou, X. and Ouyang, D. "Formulation and development of novel control release transdermal patches of carvedilol to improve bioavailability for the treatment of heart failure." *Saudi Journal of Biological Sciences* 29.1 (2022): 266-272.
 19. Victoria, C., Cottrell, J. and South, C. "Transdermal Delivery Patch." United States Patent, 28th may (2015): 1-33.
 20. Hanumanaik, M., Patil, U., Kumar, G., Patel, S.K., Singh, I. and Jadatkar, K. "Design, evaluation and recent trends in transdermal drug delivery system: a review." *International Journal of pharmaceutical sciences and research* 3.8 (2012): 2393-2406.

Source of support: Nil; **Conflict of interest:** Nil.

Cite this article as:

Fatima, S. and Deepika, B. "Future Perspectives of Transdermal Patches- A Review." *Sarcouncil Journal of Medicine and Surgery* 1.8 (2022): pp 1-4.